Work

A phase I study of the novel immunotoxin, MT-5111, in subjects (subj) with HER-2 positive tumors: Interim results.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.e15567

Authors: Zev A. Wainberg, Minal A. Barve, Erika Paige Hamilton, Andrew Jacob Brenner, Frances Valdes, Monica M. Mita, Valeria González, Banmeet S. Anand, Christine Burnett, Joshua Pelham, Roger J. Waltzman, Thomas Strack, Brian A. Van Tine

Institutions: University of California, Los Angeles, Mary Crowley Cancer Research Center, Sarah Cannon, Tennessee Oncology, The University of Texas at San Antonio Health Science Center, Mays Cancer Center at UT Health San Antonio, University of Miami, Cedars-Sinai Medical Center, Translational Research in Oncology, Molecular Templates (United States), Washington University in St. Louis

Language: English

Topic: Toxin Mechanisms and Immunotoxins

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3032596845

Cites:

Cited by: 3

Related to: 10